ARASTEP

The ARASTEP trial is a randomised, double-blind, placebo-controlled Phase 3 study of Darolutamide plus androgen deprivation therapy (ADT), compared with placebo plus ADT, in patients with high-risk biochemical recurrence (BCR) of prostate cancer.

The primary objective of this trial is to determine if Darolutamide plus ADT given for 24 months improves progression free survival by PSMA PET/CT compared with placebo plus ADT given for 24 months.

See All
CaverSTIM

World first medical device implantation to restore erectile function
ProstACT GLOBAL

A global study to evaluate investigational radionuclide therapy
STM-416p

Administered Intraoperatively to Patients Undergoing Radical Prostatectomy
Probing the Prostate

Screening for People with a Prostate
ACT for Erectile Dysfunction

Erectile Dysfunction Adaptation of ACT for Compliance with an Erectile Rehabilitation Program
RASOR

Robotics-Assisted Surgical Outcomes Registry
GenI-AIRSPACE

Genomically informed active surveillance in prostate cancer
Tissue Banking

We contribute over 60% of the advanced metastatic prostate cancer samples analysed globally.
Pan Prostate Cancer Group

As part of this global group we analyse genetic data from over 1800 men with prostate cancer.
Genetic Research Program

Identifying different types of prostate cancer and enabling targeted treatment.
Ironman Study

International registry for men with advanced prostate cancer.
PRECEPT

Improving methods of diagnosis treatment for individuals with potentially lethal prostate cancer.
Survivorship Research

Identifying different types of prostate cancer and enabling targeted treatment.